INDEMNITY AGREEMENTIndemnification Agreement • April 21st, 2023 • Vallon Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of _________, ______, is made by and between GRI BIO, INC., a Delaware corporation (the “Company”), and ______________ (“Indemnitee”).
SEPARATION AGREEMENTSeparation Agreement • April 21st, 2023 • Vallon Pharmaceuticals, Inc. • Pharmaceutical preparations • Pennsylvania
This Separation Agreement (this “Agreement”) is made and entered into as of April 21, 2023, by and between David Baker (“Executive”) and GRI Bio, Inc. (f/k/a Vallon Pharmaceuticals, Inc.) (the “Company”). The Company and Executive are sometimes collectively referred to herein as the “Parties” and individually as a “Party”.
GRI BIO, INC. CONSULTING AGREEMENTConsulting Agreement • April 21st, 2023 • Vallon Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Consulting Agreement (this “Agreement”) is made and entered into as of January 9, 2023 (the “Effective Date”) by and between GRI Bio, Inc. (the “Company”), and Albert Agro, M. D. (“Consultant”).
WARRANT TO PURCHASE COMMON STOCK April 21, 2023Warrant Agreement • April 21st, 2023 • Vallon Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received [•] (the “Warrantholder”) is entitled to subscribe for and purchase from GRI Bio, Inc., a Delaware corporation (the “Company”), subject to the terms set forth below, [•] shares (the “Warrant Shares”) of Common Stock of the Company (“Common Stock”), upon surrender hereof, at the principal office of the Company referred to below, with the Notice of Exercise attached as Exhibit A hereto duly executed, and simultaneous payment therefor in lawful money of the United States, cancellation of indebtedness, net issuance in accordance with Section 2 below or any combination thereof. The term “Exercise Price” means the Closing Per Share Price, as defined in that certain Securities Purchase Agreement, dated December 13, 2022, by and among the Company, Vallon Pharmaceuticals, Inc. (“Vallon”) and Altium Growth Fund, LP (the “Primary Financing SPA”). The term “Warrant” as used herein shall include this Warrant and any warrants delivered in substitution or excha
